Project Grant HT94252410567
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$844K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
This federal Project Grant award, valued at $168,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida, to cotarget Type 1 PRMTS and YAP1 in order to combat EGFR-mutant lung adenocarcinoma. The grant period runs from September 1, 2024 to August 31, 2025. The Moffitt Cancer Center is a nonprofit,...
The U.S. Department of Defense's Defense Health Agency has awarded a $762,168 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a project period from September 30, 2023 to September 29, 2026, is intended to "DECONVOLUTE KEY BIOLOGICAL DRIVERS THAT DEFINE SUBSETS OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN." As a leading National Cancer...
The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $328,574 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The award supports research to quantify the spatial properties of immunosuppressive macrophages in papillary renal cell carcinoma, with a performance period from July 1, 2025 to June 30, 2028. As a National Cancer Institute-designated comprehensive...
The U.S. Defense Health Agency awarded a $968,875 Project Grant under CFDA 12.420 "Military Medical Research and Development" to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, titled "IDENTIFICATION AND ASSESSMENT OF TARGETS FOR IMMUNOTHERAPY IN NF2-ASSOCIATED SCHWANNOMATOSIS", will fund advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The research will...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring...
The federal Project Grant award of $1,619,065.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "DYNAMIC: DEVELOPMENT OF A BEHAVIORAL INTERVENTION FOR YOUNG ADULTS WITH ADVANCED CANCER" project at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, FL. This grant will fund the development and evaluation of a behavioral intervention to support young adults with advanced cancer over the 4-year...
The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research to track the transformation of lung adenocarcinoma to small cell lung cancer at a single-cell level. The $705,263 award was granted to Northwestern University, a prominent private research institution, with a performance period from September 30, 2024 to September 29, 2027. This research aims to provide insights into the mechanisms underlying the...
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...